Helix BioPharma Corp. to Explore Growth Opportunities
Marketwire Canada - Thu Dec 04, 4:38PM CST
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Company has begun a comprehensive exploration of growth opportunities available to it.
HBP: 3.22 (-0.01), HBP.TO: 1.64 (-0.01)
Huttig Building Products, Inc. Announces Third Quarter 2014 Results
Marketwired - Thu Oct 30, 5:00AM CDT
Huttig Building Products, Inc. (Huttig, or the Company) (NASDAQ: HBP), a leading domestic distributor of millwork, building materials and wood products, today reported financial results for the third quarter ended September 30, 2014.
HBP: 3.22 (-0.01)
Helix BioPharma Corp. Announces Fiscal 2014 Results
Marketwire Canada - Thu Oct 23, 7:35PM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the year ended July 31, 2014.
HBP: 3.22 (-0.01), HBP.TO: 1.64 (-0.01)
Helix Reports on Interim Review of the Polish L-DOS47 Monotherapy Study in Non-Small Cell Lung Cancer
Marketwire Canada - Tue Sep 30, 7:31AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has completed its interim data review of the first eight cohorts of the Company's ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland ("LDOS002"
HBP: 3.22 (-0.01), HBP.TO: 1.64 (-0.01)
Helix BioPharma Corp. Initiates Enrollment for Tenth Cohort in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47
Marketwire Canada - Fri Sep 26, 4:00PM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the tenth dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland ("LDOS002"
HBP: 3.22 (-0.01), HBP.TO: 1.64 (-0.01)
Helix BioPharma Corp. to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland
Marketwire Canada - Thu Sep 25, 4:00PM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it will be presenting at the 2nd Global Life Sciences Conference to be held on October 2, 2014 in Warsaw, Poland, on the trading floor of the Warsaw Stock Exchange. The conference is sponsored by WedBush Europe and WDM Capital. Over 100 of Central and Eastern Europe's top life science institutional investors, funds, and analysts are expected to attend the Conference.
HBP: 3.22 (-0.01), HBP.TO: 1.64 (-0.01)
Huttig Building Products, Inc. Announces Second Quarter 2014 Results
Marketwire - Thu Jul 31, 5:01AM CDT
Huttig Building Products, Inc. (Huttig, or the Company) (NASDAQ: HBP), a leading domestic distributor of millwork, building materials and wood products, today reported financial results for the second quarter ended June 30, 2014.
HBP: 3.22 (-0.01)
Helix BioPharma Corp. Appoints New Independent Chair of the Board
Marketwire Canada - Mon Jul 21, 8:15AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the appointment of Mr. Yvon Bastien as the new Chair of the board effective July 17, 2014. Mr. Bastien has served as an independent director of the Company since December 2013 and remains the Chair of the board's Governance & Compensation Committee. Mr. Robert Verhagen has served as Interim Chair since December 2013 and remains a Director of the Company and President and CEO.
HBP: 3.22 (-0.01), HBP.TO: 1.64 (-0.01)
Helix BioPharma Corp. Announces Completion of Private Placement
Marketwire - Fri Jul 11, 7:00AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has completed a private placement with net proceeds in excess of CAD5.4 million, after fees and expenses associated with the placement.
HBP: 3.22 (-0.01), HBP.TO: 1.64 (-0.01)
Helix BioPharma Corp. Announces the Receipt of Subscription Agreements for a Net CAD5.4 Million Private Placement
Marketwire Canada - Mon Jul 07, 6:25AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has received private placement subscription agreements for common shares and warrants for aggregate net proceeds in excess of CAD5.4 million after expected expenses. Proceeds of the placement will be used for working capital to support the Company's expanding clinical trial initiatives.
HBP: 3.22 (-0.01), HBP.TO: 1.64 (-0.01)
Huttig Building Products, Inc. Set to Join Russell Microcap Index
Marketwire - Thu Jun 26, 3:00PM CDT
Huttig Building Products, Inc. (NASDAQ: HBP) is set to join the Russell Microcap(R) Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27, according to a preliminary list of additions posted June 13 on www.russell.com/indexes.
HBP: 3.22 (-0.01)